相关实验视频

Updated: May 5, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

功能增强的SLC4A3突变导致短QT综合征:从分子分析到新型诊断测试

Moshe Giladi¹, Odelia Chorin², Silvia Piccirillo³

¹Internal Medicine Division, Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel.

JACC. Clinical electrophysiology

|May 29, 2025

概括

一种新的SLC4A3基因变异,p.R1016G,导致短QT综合征 (SQTS),具有功能增益效应. 新的Ippon测试通过评估QT间隔对胸的反应来准确识别SQTS载体.

科学领域:

心血管遗传学心血管遗传学
分子心脏病学分子心脏病学
电子生理学电子生理学

背景情况:

先天性短QT综合征 (SQTS) 是一种罕见的遗传疾病,与心电图上的QT间隔缩短有关.
SQTS显著增加了危及生命的心室节律失常和心脏突然死亡的风险.

研究的目的:

识别和描述与SQTS相关的SLC4A3基因中的新型变异.
为了研究这种新的SQTS变异的分子和临床表现.

主要方法:

整个外体序列测定在SLC4A3基因中发现了一种新的误解变异 (p.R1016G).
在HEK293细胞中的计算建模和功能研究评估了变体的影响.
患者接受了心电图,霍尔特监测和一种新的挑测试 (伊波恩测试).

主要成果:

异性SLC4A3 p.R1016G变体在一个家庭中发现,该家庭有多次心脏突然死亡和心室动脉冲动.
功能分析显示了功能增强效应,与SLC4A3变体的先前发现相反.
伊波恩试验在区分载体方面表现出高准确性,通过揭示在诱导胸期间无法延长QT间隔.

结论:

该SLC4A3 p.R1016G变体是SQTS的新型原因,其特点是功能获取机制.
伊波恩测试是一个有前途的新诊断工具,可以更准确地识别SQTS变种携带者.

关键词:

在 QT 间隔.多态心室性心跳动.短时间QT综合征突发死亡突发死亡腹腔动是一种心房动.

更多相关视频

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...